Does the use of adjunct urine lipopolysaccharide lipoarabinomannan in HIV-infected hospitalized patients reduce the utilization of healthcare resources? A post hoc analysis of the LAM multi-country randomized controlled trial | Zendy

Poobalan Naidoo | Zendy; Aliasgar Esmail | Zendy; Jonny Peter | Zendy; Malika Davids | Zendy; Mohammed Fadul | Zendy; Keertan Dheda | Zendy

Open Access

Does the use of adjunct urine lipopolysaccharide lipoarabinomannan in HIV-infected hospitalized patients reduce the utilization of healthcare resources? A post hoc analysis of the LAM multi-country randomized controlled trial

Author(s) -

Poobalan Naidoo,

Aliasgar Esmail,

Jonny Peter,

Malika Davids,

Mohammed Fadul,

Keertan Dheda

Publication year - 2018

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2018.09.024

Subject(s) - medicine , lipoarabinomannan , randomized controlled trial , sputum , adjunctive treatment , tuberculosis , post hoc analysis , emergency medicine , intensive care medicine , mycobacterium tuberculosis , pathology

The World Health Organization (WHO) recommends the use of adjunctive urine lipopolysaccharide lipoarabinomannan (LAM) testing in hospitalized HIV-infected persons with suspected tuberculosis (TB) and a CD4 count <100cells/ml. However, the recommendation is conditional, and uptake by individual treatment programmes depends on perceived additional benefit. The aim of this study was to determine whether adjunctive LAM testing has additional clinical benefits including a reduction in healthcare-related use of resources.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research